Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* males and females, 18 to 50 years of age~* non-smoking or light-smoking (≤5 cigarettes per day) volunteers~* BMI ≥ 40 kg/m2~* female subjects of childbearing potential either surgically sterilized, using an effective method of contraception (diaphragm, cervical cap,condom) or agree to abstain from sex from time of pre-study screening, during entire study period and 1 week following the study period.~Exclusion Criteria:~* history of significant hypersensitivity reaction to oseltamivir~* history of gastric bypass surgical procedure~* history of significant clinical illness requiring pharmacological management~* abnormal serum electrolyte or complete blood count requiring further clinical work-up~* transaminases (AST or ALT) \>2.5 x upper limit of normal~* estimated creatinine clearance \<50 mL/min (Cockcroft-Gault equation)~* positive urine pregnancy test (if female)~* abnormal electrocardiogram (ECG) as judged by study physician~* unable to tolerate venipuncture and multiple blood draws~* clinically significant abnormal physical examination defined as a physical finding requiring further clinical work-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Oseltamivir Dosed Group (Type: EXPERIMENTAL): Oseltamivir 75 mg by mouth every 12 hours for 9 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).